Np mrd loader

Record Information
Version2.0
Created at2024-09-11 14:27:46 UTC
Updated at2024-09-11 14:27:46 UTC
NP-MRD IDNP0338226
Secondary Accession NumbersNone
Natural Product Identification
Common NameFerrlecit
Description Ferrlecit was first documented in 2005 (PMID: 15957553). Based on a literature review a significant number of articles have been published on Ferrlecit (PMID: 29999818) (PMID: 33621099) (PMID: 30676753) (PMID: 29857115) (PMID: 29439469) (PMID: 29303999).
Structure
Thumb
SynonymsNot Available
Chemical FormulaC24H44FeNaO28
Average Mass859.4230 Da
Monoisotopic Mass859.12662 Da
IUPAC Nameiron(3+) sodium tetrakis(2,3,4,5,6-pentahydroxyhexanoate)
Traditional Nameiron(3+) sodium tetragluconate
CAS Registry NumberNot Available
SMILES
[Na+].[Fe+3].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O
InChI Identifier
InChI=1/4C6H12O7.Fe.Na/c4*7-1-2(8)3(9)4(10)5(11)6(12)13;;/h4*2-5,7-11H,1H2,(H,12,13);;/q;;;;+3;+1/p-4
InChI KeyOZNJXEMJJHFYON-UHFFFAOYNA-J
Experimental Spectra
Not Available
Predicted Spectra
Not Available
Chemical Shift Submissions
Not Available
Species
Species of OriginNot Available
Chemical Taxonomy
ClassificationNot classified
Physical Properties
StateNot Available
Experimental Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Predicted Properties
PropertyValueSource
logP-3.4ChemAxon
pKa (Strongest Acidic)3.39ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area141.28 ŲChemAxon
Rotatable Bond Count20ChemAxon
Refractivity49.11 m³·mol⁻¹ChemAxon
Polarizability16.75 ųChemAxon
Number of Rings0ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
HMDB IDNot Available
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FoodDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkSodium ferric gluconate complex
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI IDNot Available
Good Scents IDNot Available
References
General References
  1. Authors unspecified: Sodium Ferric Gluconate Complex.. 2006. [PubMed:29999818 ]
  2. Brandis JEP, Kihn KC, Taraban MB, Schnorr J, Confer AM, Batelu S, Sun D, Rodriguez JD, Jiang W, Goldberg DP, Langguth P, Stemmler TL, Yu YB, Kane MA, Polli JE, Michel SLJ: Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. Mol Pharm. 2021 Apr 5;18(4):1544-1557. doi: 10.1021/acs.molpharmaceut.0c00922. Epub 2021 Feb 23. [PubMed:33621099 ]
  3. Neu HM, Alexishin SA, Brandis JEP, Williams AMC, Li W, Sun D, Zheng N, Jiang W, Zimrin A, Fink JC, Polli JE, Kane MA, Michel SLJ: Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach. Mol Pharm. 2019 Mar 4;16(3):1272-1281. doi: 10.1021/acs.molpharmaceut.8b01215. Epub 2019 Feb 14. [PubMed:30676753 ]
  4. Pai AB, Pai MP, Meyer DE, Bales BC, Cotero VE, Zheng N, Jiang W: In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations. Regul Toxicol Pharmacol. 2018 Aug;97:17-23. doi: 10.1016/j.yrtph.2018.05.014. Epub 2018 May 29. [PubMed:29857115 ]
  5. Matta MK, Beekman CR, Gandhi A, Narayanasamy S, Thomas CD, Mohammad A, Stewart S, Xu L, Chockalingam A, Shea K, Patel V, Rouse R: Determination of Non-Transferrin Bound Iron, Transferrin Bound Iron, Drug Bound Iron and Total Iron in Serum in a Rats after IV Administration of Sodium Ferric Gluconate Complex by Simple Ultrafiltration Inductively Coupled Plasma Mass Spectrometric Detection. Nanomaterials (Basel). 2018 Feb 11;8(2):101. doi: 10.3390/nano8020101. [PubMed:29439469 ]
  6. Sun D, Rouse R, Patel V, Wu Y, Zheng J, Karmakar A, Patri AK, Chitranshi P, Keire D, Ma J, Jiang W: Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Physicochemical Characterization. Nanomaterials (Basel). 2018 Jan 5;8(1):25. doi: 10.3390/nano8010025. [PubMed:29303999 ]
  7. Span K, Pieters EHE, Brinks V, Hennink WE, Schellekens H: Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations. J Pharmacol Toxicol Methods. 2018 May-Jun;91:7-17. doi: 10.1016/j.vascn.2017.12.001. Epub 2017 Dec 24. [PubMed:29278742 ]
  8. Wu M, Sun D, Tyner K, Jiang W, Rouse R: Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake. Nanomaterials (Basel). 2017 Dec 15;7(12):451. doi: 10.3390/nano7120451. [PubMed:29244729 ]
  9. Kesselheim AS, Polinski JM, Fulchino LA, Isaman DL, Gagne JJ: Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes. Drugs. 2015 Apr;75(6):633-50. doi: 10.1007/s40265-015-0382-1. [PubMed:25822610 ]
  10. Thomas A, Peterson LE: Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis. 2014 May 20;7:191-201. doi: 10.2147/IJNRD.S65158. eCollection 2014. [PubMed:24899820 ]
  11. Seng Yue C, Gallicano K, Labbe L, Ducharme MP: Novel population pharmacokinetic method compared to the standard noncompartmental approach to assess bioequivalence of iron gluconate formulations. J Pharm Pharm Sci. 2013;16(3):424-40. doi: 10.18433/j3hs42. [PubMed:24021291 ]
  12. Futterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P: Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal. 2013 Dec;86:151-60. doi: 10.1016/j.jpba.2013.08.005. Epub 2013 Aug 14. [PubMed:23998966 ]
  13. Baribeault D: Short-term stability of a new generic sodium ferric gluconate in complex with sucrose. Curr Med Res Opin. 2011 Dec;27(12):2241-3. doi: 10.1185/03007995.2011.628304. Epub 2011 Oct 12. [PubMed:21992082 ]
  14. Baribeault D: Sodium ferric gluconate (SFG) in complex with sucrose for IV infusion: bioequivalence of a new generic product with the branded product in healthy volunteers. Curr Med Res Opin. 2011 Aug;27(8):1653-7. doi: 10.1185/03007995.2011.597738. Epub 2011 Jun 30. [PubMed:21714710 ]
  15. Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, Hofmeister W, Munoz M, Bock K, Meldal M, Langguth P: A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011 Aug;78(3):480-91. doi: 10.1016/j.ejpb.2011.03.016. Epub 2011 Mar 23. [PubMed:21439379 ]
  16. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C: Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010 Sep;85(9):650-4. doi: 10.1002/ajh.21794. [PubMed:20661919 ]
  17. Drynda A, Hoehn R, Peuster M: Influence of Fe(II) and Fe(III) on the expression of genes related to cholesterol- and fatty acid metabolism in human vascular smooth muscle cells. J Mater Sci Mater Med. 2010 May;21(5):1655-63. doi: 10.1007/s10856-010-4014-8. Epub 2010 Feb 17. [PubMed:20162334 ]
  18. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006 Mar-Apr;19(2):161-7. [PubMed:16736414 ]
  19. Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, Opacic M, Simic T, Dimkovic N, Simic DV: Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail. 2005;27(3):345-51. doi: 10.1081/jdi-56599. [PubMed:15957553 ]